Risk Calculators

This information is provided by Cleveland Clinic as a convenience service only to physicians and is not intended to replace the physicians' medical advice. Please remember that this information, in the absence of a visit with a physician's patient, must always be considered as an educational service only and are not designed to replace a physician's independent judgment about the appropriateness or risks of a procedure or recommendations for a given patient. CCF makes no representation or warranty concerning the accuracy or reliability of this information and does not warrant the results of using this tool. In no event shall CCF be liable for any damages, direct, indirect, consequential or otherwise, relating to the use of this information or this tool. 

---

Please choose one of the following or for keyword

Lastest calculators from CCF authors:

Patients Undergone Ileal Pouch Analanastomosis (IPAA):

• Patients Undergone Ileal Pouch Analanastomosis (IPAA)
  

Predictive Risk Model for Mortality:

• Predictive Risk Model for Mortality
  In Critically Ill Patients with AKI Requiring Dialysis

Urinary and Fecal Incontinence Nomogram with planned mode of delivery predictor:

• Urinary and Fecal Incontinence Nomogram with planned mode of delivery predictor
  Jelovsek

Prostate Cancer:

• Patients at high risk for prostate cancer
  with a prior negative 6 to 12 core biosy in the past 6 months. Limitations on the allowable values for the risk predictors are based on the entry criteria of the REDUCE trial.

Lastest calculators from non-CCF authors:

Sírio-Libanês Hospital, Brazil:

• Upper Limb Volume Calculator
  

University Medical Center Rotterdam:

• A Prediction Model for the Presence of Coronary Artery Disease
  The CAD consortium

Core published CCF calculators:

Benign Prostate Hyperplasia:

• Benign Prostate Hyperplasia
  Predicting Acute Urinary Retention or Surgical Intervention within 2 years (with or without Dutasteride)

Bladder Cancer:

• Bladder Cancer
  5-Year Recurrence-Free Survival after Radical Cystectomy

Breast Cancer:

• Predicting Positive Non-Sentinal Lymph Node in Patients with Positive SLN (with Frozen Section Info)
• Predicting Positive Non-Sentinal Lymph Node in Patients with Positive SLN (without Frozen Section Info)
• Predicting Sentinel Lymph Node Metastasis (with Pre-Operative Information including ER/PR)
• Predicting Sentinel Lymph Node Metastasis (without Pre-Operative Information)

Colorectal Cancer:

• Complex Colorectal Surgery
  30-Day Risk of Postoperative Organ Space Surgical Site Infection
• Predicting 5 and 10 Year Recurrence-Free Survival using Post-Op Info
• Predicting 96-Month Disease Specific Survival after Hepatic Resection

Coronary Artery Disease:

• Suspected Coronary Artery Disease
  Predicting Long-Term Survival (for suspected patients with a normal electrocardiogram)

Diabetes:

• Type 2 Diabetes
  Predicting 6-Year Mortality Risk

Gastric Cancer:

• Predicting Postoperative Disease-Specific Survival Following an R0 Resection

Joint Replacement:

• Total Joint Arthroplasty
  Predicting Patient Discharge Disposition

Kidney Cancer:

• Prediction of Cancer, Aggressive Cancer, and Freedom from Metastases

Kidney Transplant:

• Predicting Graft Survival at 5-Years Using Pre-Transplant and 6-Month Info

Kidney Transplant\n:

• Graft Survival at 5-Years and eGFR at 1-Year using Pre-Transplant Information

Melanoma:

• Predicting Positive Sentinel Lymph Nodes

Oral Cavity Squamous Cell Carcinoma:

• Predicting 5-Year Locoregional Recurrence-Free Survival

Ovarian Cancer:

• Predicting Survival after Primary Surgery for Bulky Stage IIIC Carcinoma

Pancreatic Cancer:

• Predicting 12, 24, and 36-Month Survival after Resection for Adenocarcinoma of the Pancreas

Penile Cancer:

• Predicting 5-Year Survival and Lymph-Node Involvement

Prostate Cancer:

• Predicting Cancer Risk Following Initial Biopsy
• Predicting Cancer Risk Following Repeated Biopsy
• Predicting Increased Pathologic Gleason Score
• Predicting PSA Recurrence Following Salvage Radiation Therapy
• Predicting Post-Treatment Freedom from Recurrence
• Pretreatment - Predicting Indolent Cancer, Freedom from Recurrence, Metastasis, Survival, and Trifecta

Prostate Cancer\n:

• Metastatic Prostate Cancer\n
  Overall Survival after Castration

Sarcoma:

• Predicting Disease-Specific Death after Local Recurrence (with competing risks present)
• Predicting Post-Operative 12-Year Disease-Specific Mortality

---